Guidelines for Use
Our guideline named OLUTASIDENIB (Rezlidhia) requires the following rule(s) be met for approval:
- You have relapsed or refractory acute myeloid leukemia (AML: a type of blood cancer that has returned or did not respond to treatment)
- You are 18 years of age or older
- You have a susceptible (can be treated with the drug) isocitrate dehydrogenase-1 (IDH1: a type of enzyme) mutation as detected by a Food and Drug Administration (FDA)-approved test
Rationale
Promote appropriate utilization of OLUTASIDENIB based on FDA approved indication and dosage.
Indications for Use
Rezlidhia is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Dosage and Administration
The recommended dosage of Rezlidhia is 150 mg orally twice daily, until disease progression or unacceptable toxicity.
References
Rezlidhia [Prescribing Information]. Greenville, NC: Forma Therapeutics, Inc., December 2022.